Genetically Modifying Patients’ Skin Cells to Treat Rare Diseases

Matthew Gantz, president and CEO of Castle Creek Biosciences, discusses the company’s experimental therapy for RDEB, how it works, and how the company is building out its pipeline through dealmaking.